In this video, Motley Fool health care bureau chief Brenton Flynn previews the Fool's premium report on Abbott Labs by outlining some risks facing the company. First, all of its business segments operate in highly competitive environments. Second, Abbott's international businesses are vulnerable to currency fluctuations and economic downturns, such as we see now in Europe. These downturns reduce consumer demand for Abbott's nutritional products, for example. Lastly, many foreign countries have a single-payor system for health care, and these might force Abbott to take suboptimal payments for its products.
Learn more in our premium report
Abbott Labs has changed forever after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's brand new premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.